EPHA7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1227526	0.73	2/20
SCHEMBL1227708	0.71	2/20
SCHEMBL1227432	0.69	2/20
SCHEMBL1227471	0.68	2/20
SCHEMBL1227756	0.67	2/20
SCHEMBL1226728	0.66	2/20
SCHEMBL2251439	0.65	2/20
SCHEMBL1227646	0.63	2/20
SCHEMBL1228195	0.63	2/20
SCHEMBL1401644	0.62	2/20
SCHEMBL1401645	0.62	2/20
SCHEMBL1401716	0.62	2/20
SCHEMBL1401718	0.62	2/20
SCHEMBL1401788	0.62	2/20
SCHEMBL1401789	0.62	2/20
SCHEMBL1401643	0.61	2/20
SCHEMBL1401686	0.61	2/20
SCHEMBL2252302	0.60	2/20
SCHEMBL2255402	0.60	2/20
SCHEMBL2249540	0.58	2/20

Clinical trials — most relevant to EPHA7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction	PHASE4	COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer	PHASE2	COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules	PHASE2	UNKNOWN
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC	PHASE1/PHASE2	UNKNOWN
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
AZD7451 for Recurrent Gliomas	PHASE1	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Genetics of Arteriovenous Malformations	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)	nan	RECRUITING
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EPHA7 binder may also engage these)

Protein	Name	Similarity
O42422	—	1.000	O42422 →
EPHA5	Ephrin type-A receptor 5	1.000	landscape →
Q91735	—	1.000	Q91735 →
Q91694	—	1.000	Q91694 →
Q90344	—	1.000	Q90344 →
Q03137	—	1.000	Q03137 →
Q03145	—	1.000	Q03145 →
P54759	—	1.000	P54759 →
Q07496	—	1.000	Q07496 →
P29319	—	1.000	P29319 →
P28693	—	1.000	P28693 →
P54758	—	1.000	P54758 →
P54755	—	1.000	P54755 →
Q91845	—	1.000	Q91845 →
P54757	—	1.000	P54757 →
EPHA4	Ephrin type-A receptor 4	0.999	landscape →
EPHB1	Ephrin type-B receptor 1	0.999	landscape →
EPHB2	Ephrin type-B receptor 2	0.999	landscape →
Q07498	—	0.998	Q07498 →
EPHA6	Ephrin type-A receptor 6	0.998	landscape →
EPHA2	Ephrin type-A receptor 2	0.998	landscape →
Q60629	—	0.998	Q60629 →
Q07497	—	0.998	Q07497 →
O09127	—	0.997	O09127 →
Q8CBF3	—	0.997	Q8CBF3 →
Q61772	—	0.997	Q61772 →
Q1KL86	—	0.997	Q1KL86 →
P09759	—	0.997	P09759 →
Q91736	—	0.996	Q91736 →
Q00495	—	0.996	Q00495 →